BSX - Boston Scientific Corporation
| Previous close | 42.90 |
| Open | 42.97 |
| Bid | 42.73 x 1800 |
| Ask | 44.00 x 2200 |
| Day's range | 42.79 - 43.15 |
| 52-week range | 31.56 - 43.84 |
| Volume | 6,356,818 |
| Avg. volume | 5,575,940 |
| Market cap | 60.205B |
| Beta (3Y monthly) | 0.70 |
| PE ratio (TTM) | 43.49 |
| EPS (TTM) | 0.99 |
| Earnings date | 22 Oct. 2019 - 28 Oct. 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 48.23 |
- Zacks
BAX or BSX: Which Is the Better Value Stock Right Now?
BAX vs. BSX: Which Stock Is the Better Value Option?
- Zacks
IoMT Becomes the Buzzword in New Age MedTech Investing
Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.
- Simply Wall St.
Does Boston Scientific Corporation's (NYSE:BSX) CEO Pay Reflect Performance?
Mike Mahoney has been the CEO of Boston Scientific Corporation (NYSE:BSX) since 2012. First, this article will compare...
- Zacks
Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost
In its effort to accommodate the acquisition of BTG, Boston Scientific (BSX) is offloading its certain non-prior businesses.
- Zacks
Boston Scientific (BSX) Up 1.6% Since Last Earnings Report: Can It Continue?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
BAX vs. BSX: Which Stock Is the Better Value Option?
BAX vs. BSX: Which Stock Is the Better Value Option?
- Zacks
Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod
Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.
- Zacks
Here's Why You Should Hold Varian Medical (VAR) Stock Now
Varian (VAR) raises the revenue guidance for fiscal 2019.
- Zacks
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
- Zacks
FDA Resets PAD Guidelines: The Road Ahead for Device Makers
On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.
- Zacks
Cardiovascular Systems Set to Present LIBERTY 360 Outcome
This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).
- Simply Wall St.
Don't Sell Boston Scientific Corporation (NYSE:BSX) Before You Read This
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...
- Zacks
Boston Scientific Rides on New Products Amid Dull Pacer Sales
Within MedSurg, Boston Scientific (BSX) is on track for the year-end launch of Exalt-D Single-Use Duodenoscope, which is used in ERCP procedures.
- Zacks
Top Analyst Reports: Amgen, Uber, Mondelez & More
Top Analyst Reports: Amgen, Uber, Mondelez & More
- Zacks
4 Medical Product Stocks Set to Beat This Earnings Season
Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
- Simply Wall St.
What We Think Of Boston Scientific Corporation’s (NYSE:BSX) Investment Potential
Today we'll evaluate Boston Scientific Corporation (NYSE:BSX) to determine whether it could have potential as an...
- Motley Fool
10 Biggest Medical Device Stocks
Market caps for these medical device stocks are big. Most of them have been big winners, too.
Motley FoolBoston Scientific (BSX) Q2 2019 Earnings Call Transcript
BSX earnings call for the period ending June 30, 2019.
- Motley Fool
What You'll Want to Know About Boston Scientific's Q2 Earnings
The medical device maker delivered mixed results for the second quarter.
- Zacks
Boston Scientific (BSX) Q2 Earnings Top on Growth in All Lines
Boston Scientific's (BSX) revenue strength across all business lines and geographies raises investors' optimism on the stock.
- Zacks
Boston Scientific (BSX) Surpasses Q2 Earnings Estimates
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and -0.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
What's in Store for Boston Scientific's (BSX) Q2 Earnings?
We are upbeat about solid contributions from Boston Scientific's (BSX) Cardiovascular business group, which comprises Interventional Cardiology and Peripheral Interventions.
- Zacks
Will USTR's 25% Tariff Exemption Spell Relief for MedTech?
In the wake of the U.S. tariff and Chinese retaliation, the MedTech industry players (with production houses in China) are facing huge bottom line pressure.
- Zacks
Earnings Preview: Boston Scientific (BSX) Q2 Earnings Expected to Decline
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
US-India Trade Tensions Rise: 3 Stocks in the Line of Fire
As India moves toward self-sufficiency, U.S. MedTech bigwigs fret over possible losses.
